RNS Number : 6139U MyHealthChecked PLC 29 March 2023

MyHealthChecked PLC

("MyHealthChecked" or the "Company")

Notice of Results

MyHealthChecked PLC (AIM: MHC), the consumer home-testing healthcare company,will announce its preliminary results for the year ended 31 December 2022 on Monday 3 April 2023.

Investor presentation

Penny McCormick, Chief Executive Officer and Nicholas Edwards, Chief Financial Officer will provide a live presentation relating to the preliminary results via the Investor Meet Company platform on Monday 3 April at 4.30pm BST.

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via the Investor Meet Company dashboard up until 9:00am BST the day before the meeting or at any time during the live presentation. Investors can sign up to Investor Meet Company for free and add to meet MyHealthChecked PLC via:

https://www.investormeetcompany.com/myhealthchecked-plc/register-investor

Investors who already follow MyHealthChecked Plc on the Investor Meet Company platform will automatically be invited.

For further information contact:

MyHealthChecked PLC

Penny McCormick, Chief Executive Officer

SPARK Advisory Partners Limited (NOMAD)

Neil Baldwin

Dowgate Capital Limited (Broker)David Poutney / Nicholas Chambers

Walbrook PR Ltd (Media & IR)
Paul McManus / Alice Woodings

Tel: +44 (0)20 3368 3550

www.myhealthchecked.com

via Walbrook PR

Tel: +44 (0)20 3903 7715

Tel: +44 (0)20 7933 8780 or myhealthcheckedplc@walbrookpr.com
Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

About MyHealthChecked PLC (www.myhealthcheckedplc.com)

MyHealthChecked PLC, based in Cardiff, is an AIM-quoted pioneering UK healthcare company focused on a range of at-home healthcare and wellness tests.

MyHealthChecked is the umbrella brand of a range of at-home DNA and RNA tests that have been developed following the acquisition of The Genome Store in November 2020. The tests are available online, and in some cases, for over-the-counter purchase.

The MyHealthChecked portfolio has been identified as part of a change in mindset as customers become more familiar with the concept of accessible healthcare in the growing at home testing kit market with a focus on accessibility at the right price, led by UK-based experts.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact msc.dec. www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our <u>Privacy Policy</u>.

END

NORGIGDXCGDDGXC